Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic Arterial Chemotherapy with Epirubicin-Entrapped WOW-Type Lipiodol Emulsion for Hepatocellular Carcinoma
jRCTs031240700Recruiting
- Sponsor
- Terumo Life Science Foundation
- Start
- Feb 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of epirubicin in hepatocellular carcinoma (HCC), sponsored by Terumo Life Science Foundation. Primary endpoint: Local treatment effect and tumor shrinkage (RECIST v1.1). Started Feb 2025; status: recruiting.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031240700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240700.